Stocks vs the economy

 Claude finished the response

The stock market does well, in spite of a less than sterling economy.  I suspect that is largely because of lots of small decisions we don't hear about from lots of regulators and such benefiting individual companies.
Weighed regulatory capture theory against dominant market drivers

That's a real phenomenon, but I don't think regulatory favoritism is the main driver — the data points somewhere more specific and, honestly, more interesting.

What's actually happening in 2026: market performance is being carried by a startlingly narrow slice of stocks. only about 17% of stocks within the S&P 500 have outperformed the index itself over the past month, one of the lowest readings in the past decade. The gains are concentrated in AI infrastructure and semiconductor names riding a capex supercycle, while the broader market — and the broader economy — looks much weaker. Stock market wealth is soaring while consumer sentiment is plunging to record lows, and corporate profits are rising while many households run down savings.
Charles Schwab
Economics Help

Two mechanisms explain most of this without needing to invoke quiet regulatory favors:

    Earnings and capex concentration. A handful of AI-adjacent giants are spending and earning at a scale that moves the index-level numbers, even as most companies see flat or negative returns. Mega-cap growth stocks have driven an 86% total return for the S&P 500 versus 43% for the Equal Weight index over three years — a gap seen only once before, in the late-1990s tech bubble.
    Oppenheimer
    The wealth effect is concentrated, not broad. Equity ownership is heavily concentrated among higher-income households, so asset owners and non-asset owners are experiencing very different economies — the stock market can look great to investors while the median household feels none of it.
    Charles Schwab

Where your instinct isn't wrong: there absolutely are regulatory and administrative decisions that quietly redirect fortune toward specific firms — tariff carve-outs, merger clearances, spectrum allocations, a favorable Fed stance on bank capital, drug approvals. Those things happen constantly and rarely make headlines. But they tend to explain why particular companies win, not why the aggregate index is disconnected from the aggregate economy. The index-level divergence is really an artifact of concentration — a small number of firms so large that their capex and earnings swamp the signal from everyone else — plus the fact that stock ownership itself is concentrated in the same households whose spending looks fine, while wage-dependent households are stretched thin.

So it's less "many small hidden regulatory thumbs on the scale" and more "a few very large, very visible thumbs" — AI capex, ownership concentration, and a Fed/rate backdrop that's been friendly to asset prices. Worth noting since you're already deep in the regulatory-and-trust-structure headspace for the estate planning work — this is a different kind of "who benefits quietly" question, but the mechanism here is scale, not stealth.

As a social and international "liberal" gaining magnificently from whatever is the cause, and I am pretty heavy into AI, it results in mixed feelings.  What you indicate has hints of bubble about it, and would at any rate indicate the administration may be misleading people when it takes credit.
Balanced tech skepticism against economist perspectives on bubbles and policy claims

Fair enough to feel conflicted — you're not wrong to notice the tension. Let's take the two pieces separately, since they're different kinds of claims.

On the bubble question: your hunch is shared by a lot of serious people, and it's genuinely contested, not fringe. The Bank for International Settlements has explicitly compared the current AI investment surge to historical episodes like canal and railway mania, 1920s electrification exuberance, and the dot-com boom, warning these all shared the trait of technological breakthroughs attracting capital beyond what commercial returns could justify. Oliver Wyman notes the "Magnificent Seven" now represent about 35% of S&P 500 value, matching the peak concentration of the dot-com bubble, and separately US equity market cap is currently nearly double GDP, higher than the dot-com peak. On the other side, the bull case is that AI is already embedded across real industries — pharma, manufacturing, energy, defense — rather than confined to speculative startups, which is a structural difference from 1999. And Eugene Fama's old point still stands: it's genuinely hard to prove something is a bubble until it pops.

So: your feeling that this "has hints of bubble about it" isn't a hunch you should discount. It puts you in the company of central bankers, not just cranks.

On the administration and credit-taking: this is where I'd separate two different claims that often get merged. That the market is at record highs is a fact. Whether the current administration's policies deserve the credit is a genuinely contested political question, and reasonable people land differently:

    The case for some credit: rate cuts, deregulation, and fiscal stimulus are real tailwinds that any administration would tout, and they're not fictional — easing monetary policy does mechanically support asset prices.
    The case against: the rally is very narrowly concentrated in AI/semiconductor mega-caps riding a private capex cycle that has little to do with any administration's actions, and the same period shows real wages squeezed, consumer sentiment near historic lows, and a widening gap between asset owners and everyone else. Crediting an index high for broad economic health, when the index gain is disproportionately a handful of stocks and household sentiment is at multi-year lows, is the kind of thing critics call cherry-picking — but that's an interpretive judgment, not something I can adjudicate for you.

Where I'd land, if I were in your chair as an AI-invested beneficiary of this: you can hold "I'm profiting from this and glad of it" and "this looks structurally overheated and I should treat gains as somewhat provisional" at the same time. Those aren't contradictory — they're just prudent.

I don't think the current AI is like the others, but they always say something like that.  My stocks dropped in half in the dot-com break, but I made up for it soon by holding on.
Weighed personal experience against speculative patterns cautiously

That's the ironic thing — "this time it's different" is the most reliable tell precisely because it gets said every time, including the times it turns out to be partly true. Radio in the 1920s, railroads before that, the internet in 1999: in every case the technology was real and did reshape the economy, and in every case the near-term pricing was still wrong. The dot-com crash didn't happen because the internet was a dud — Amazon and Google came out the other side and became some of the most valuable companies in history. It happened because too much money chased the idea too fast, before the business models caught up to the hype.

So "the tech isn't like the others" and "the market is overpriced anyway" aren't actually in tension — they can both be true at once. AI plausibly is a bigger deal, structurally, than most of what preceded it. That doesn't mean this year's valuations, financed partly through circular vendor-deals and debt rather than organic cash flow, are the right price for it.

Your dot-com experience is the classic buy-and-hold lesson, and it's a real one — a diversified position that gets cut in half can come back if you don't sell at the bottom and the underlying economy keeps growing. But it's worth noting the shape of this cycle is different in one respect: back then, even after the crash, the market as a whole wasn't so concentrated in a handful of names. Today a small number of AI/semiconductor stocks make up an unusually large share of total index value, so "holding the market" and "holding a bet on AI specifically" are closer to the same thing than they used to be. Whether that changes your calculus is really a personal risk-tolerance question rather than something I can answer for you — I'm not a financial advisor, and this isn't a recommendation either way — but it's the kind of difference that's worth having clearly in view rather than assuming 2026 will resolve the way 2001 did just because the emotional shape of the story rhymes.

No I wouldn't dream of asking your advice, and almost certainly wouldn't follow it if you gave it.
Thought for 2s

Fair enough — and honestly, that's the right instinct. I'm better used as a sparring partner for working through the logic than as a source of buy/sell signals; you've got decades of actual market experience through a real crash, which counts for more than anything I can offer on that front.

I have the same attitude about all such advice.  Those who really know, if they know, keep it to themselves.
Traced biotech acquisition and immunotherapy molecule's commercial trajectory

That sounds a lot like Medarex — a Princeton, NJ biotech with antibody technology that Bristol-Myers Squibb acquired in 2009 for about $2.4 billion, largely to get full rights to a promising Phase III compound called ipilimumab. That molecule went on to be approved in 2011 as Yervoy, one of the first checkpoint-inhibitor immunotherapy drugs for melanoma — a genuinely significant molecule in retrospect, part of the wave that led to the whole modern immuno-oncology field.

The fit with your memory is good: Princeton facility, folded into an established, much larger biotech/pharma (BMS), rather than an independent path to approval. The timing also lines up with "sold before approval" — the acquisition closed in 2009, two years before the drug actually got its FDA approval, so if you held Medarex stock, your exit would naturally have come via the buyout itself rather than you having to time an approval-news sale.

I can't be fully certain this is the one without more specific details from you — Princeton NJ has hosted a fair number of biotechs over the decades — but the combination of location, an established acquirer, and a drug that mattered enough to be worth remembering even without the name makes Medarex the strongest match. Does ipilimumab/Yervoy or Bristol-Myers Squibb ring a bell?

Doesn't matter; water under the bridge.  Thanks.

Sounds good, Frank. Enjoyable ramble through the market weirdness and some old memories — take care.
Want to be notified when Claude responds?


Claude is AI and can make mistakes. Please double-check responses.